William H. Rastetter - 16 Oct 2026 Form 4 Insider Report for Iambic Therapeutics, Inc. (IAM)

Reporting relationship: Director, Chairperson of the Board
Issuer ticker: IAM
Reported as of: 16 Oct 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Oct 2026, 19:49:30 UTC
Prior SEC filing: 14 Oct 2026
Source filing: View source filing
Reporting owner signature: /s/ Sunny Chang, by power of attorney

Filing notes and source

Key filing fact

William H. Rastetter filed Form 4 for Iambic Therapeutics, Inc. (IAM) on 19 Oct 2026.

Key facts

This page summarizes William H. Rastetter's Form 4 filing for Iambic Therapeutics, Inc. (IAM).
7 reported transactions and 5 derivative rows are listed below.
Accepted by SEC: 19 Oct 2026, 19:49.

Change

Previous filing in this sequence was filed on 14 Oct 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001205903 Primary reporting owner

RASTETTER WILLIAM H

Relationship: Director, Chairperson of the Board
Address: C/O IAMBIC THERAPEUTICS, INC., 5627 OBERLIN DRIVE, SUITE 120, SAN DIEGO
Signature: /s/ Sunny Chang, by power of attorney
Signature date: 19 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IAM transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +192,579
Change %
Price
Shares after: 192,579
Date: 16 Oct 2026
Ownership: See footnote
Footnotes: F1, F2, F3, F4, F5

IAM transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +8,341
Change %: +4.3%
Price
Shares after: 200,920
Date: 16 Oct 2026
Ownership: See footnote
Footnotes: F5, F6

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IAM transaction Derivative

Series B Convertible Preferred Stock

Conversion of derivative security

Transaction value
Shares: -76,801
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 16 Oct 2026
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 76,801
Exercise price
Footnotes: F1, F5

IAM transaction Derivative

Series B-2 Convertible Preferred Stock

Conversion of derivative security

Transaction value
Shares: -64,001
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 16 Oct 2026
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 64,001
Exercise price
Footnotes: F2, F5

IAM transaction Derivative

Series B-3 Convertible Preferred Stock

Conversion of derivative security

Transaction value
Shares: -36,805
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 16 Oct 2026
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 36,805
Exercise price
Footnotes: F3, F5

IAM transaction Derivative

Series B-4 Convertible Preferred Stock

Conversion of derivative security

Transaction value
Shares: -14,972
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 16 Oct 2026
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 14,972
Exercise price
Footnotes: F4, F5

IAM transaction Derivative

Convertible Promissory Notes

Conversion of derivative security

Transaction value
Shares: -8,341
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 16 Oct 2026
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 8,341
Exercise price
Footnotes: F5, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

Footnote F2

Each share of Series B-2 Convertible Preferred Stock automatically converted into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

Footnote F3

Each share of Series B-3 Convertible Preferred Stock automatically converted into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

Footnote F4

Each share of Series B-4 Convertible Preferred Stock automatically converted into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

Footnote F5

The shares are held of record by the Rastetter Family Trust dated September 2, 2010, for which Dr. Rastetter serves as a trustee.

Footnote F6

The conversion price was equal to 85% of the Issuer's initial public offering price of $16.00 per share (reflecting a 15% discount).

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .